Last A$1.18 AUD
Change Today +0.33 / 38.82%
Volume 83.7K
PGL On Other Exchanges
As of 2:10 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

progen pharmaceuticals ltd (PGL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/26/14 - A$1.29
52 Week Low
07/26/13 - A$0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

progen pharmaceuticals ltd (PGL) Related Businessweek News

No Related Businessweek News Found

progen pharmaceuticals ltd (PGL) Details

Progen Pharmaceuticals Limited, a biotechnology company, discovers, researches, and develops biopharmaceutical therapeutics for the treatment of human diseases in Australia and the United States. It focuses on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The company’s products in research and development stage include PG545, an anti-cancer compound in preclinical development; and PI-88 melanoma program that is in Phase 2 clinical development stage. It also provides contract services related to the process development, manufacture, and quality assurance of biological products. The company, formerly known as Progen Industried Limited, was incorporated in 1989 and is based in Darra, Australia.

Founded in 1989

progen pharmaceuticals ltd (PGL) Top Compensated Officers

General Manager of Finance
Total Annual Compensation: A$73.6K
Chief Executive Officer PharmaSynth Pty Ltd
Total Annual Compensation: A$140.0K
Company Secretary
Total Annual Compensation: A$18.4K
Director of Business Development & Legal
Total Annual Compensation: A$176.7K
Compensation as of Fiscal Year 2013.

progen pharmaceuticals ltd (PGL) Key Developments

Progen Pharmaceuticals Limited Announces Change of Head Office Address

Progen Pharmaceuticals Ltd. advised that its registered address has changed to: Level 18, 101 Collins Street, Melbourne, VIC 3000. The company's main telephone and fax numbers remain unchanged.

Progen Pharmaceuticals Limited Announces Completion of First Patient Cohort in its PG545 Phase 1 Clinical Trial

Progen Pharmaceuticals Limited announced that it has completed treatment of the first patient cohort in its PG545 Phase 1 clinical trial. Progen together with an independent medical monitor and the co-ordinating investigator have reviewed the safety data from this cohort and have agreed to progress to the next higher dose of PG545. The first group of three patients were treated at the Linear Clinical Research Unit operating out of the Sir Charles Gairdner Hospital in Perth, Western Australia. Each patient in this group received once-weekly 25mg doses of PG545. No dose limiting toxicities or significant adverse events were reported from the group following at least four weeks of treatment. Accordingly, the recruitment of the second group of three patients has commenced. Each of the patients in the second group will receive 50mg doses of PG545 at once-weekly intervals.

Progen Pharmaceuticals Limited to Relocate its Corporate Office to Melbourne

Progen Pharmaceuticals Limited has decided to relocate the company’s corporate office to Melbourne. The company’s wholly-owned subsidiary PharmaSynth Pty Ltd, will continue to operate out of its existing facility in Darra, Queensland. The company will provide further details of the new registered office address in Melbourne in due course.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGL:AU A$1.18 AUD +0.33

PGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation PGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGEN PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at